179 related articles for article (PubMed ID: 8402658)
1. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
Torrisi R; Pensa F; Orengo MA; Catsafados E; Ponzani P; Boccardo F; Costa A; Decensi A
Cancer Res; 1993 Oct; 53(20):4769-71. PubMed ID: 8402658
[TBL] [Abstract][Full Text] [Related]
2. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
[TBL] [Abstract][Full Text] [Related]
3. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
Formelli F
J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.
Decensi A; Johansson H; Miceli R; Mariani L; Camerini T; Cavadini E; Di Mauro MG; Barreca A; Gonzaga AG; Diani S; Sandri MT; De Palo G; Formelli F
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1047-53. PubMed ID: 11588130
[TBL] [Abstract][Full Text] [Related]
5. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
[TBL] [Abstract][Full Text] [Related]
6. Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer.
Serrano D; Baglietto L; Johansson H; Mariette F; Torrisi R; Onetto M; Paganuzzi M; Decensi A
Clin Cancer Res; 2005 Mar; 11(5):2083-8. PubMed ID: 15756035
[TBL] [Abstract][Full Text] [Related]
7. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
Formelli F; Carsana R; Costa A; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M
Cancer Res; 1989 Nov; 49(21):6149-52. PubMed ID: 2529028
[TBL] [Abstract][Full Text] [Related]
8. Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.
Guerrieri-Gonzaga A; Robertson C; Bonanni B; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Formelli F; Intra M; Latronico A; Franchi D; Pelosi G; Johnson K; Decensi A
J Clin Oncol; 2006 Jan; 24(1):129-35. PubMed ID: 16382122
[TBL] [Abstract][Full Text] [Related]
9. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.
Costa A; Formelli F; Chiesa F; Decensi A; De Palo G; Veronesi U
Cancer Res; 1994 Apr; 54(7 Suppl):2032s-2037s. PubMed ID: 8137334
[TBL] [Abstract][Full Text] [Related]
10. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium.
Kurie JM; Lee JS; Khuri FR; Mao L; Morice RC; Lee JJ; Walsh GL; Broxson A; Lippman SM; Ro JY; Kemp BL; Liu D; Fritsche HA; Xu X; Lotan R; Hong WK
Clin Cancer Res; 2000 Aug; 6(8):2973-9. PubMed ID: 10955773
[TBL] [Abstract][Full Text] [Related]
11. [Breakthrough in breast cancer chemoprevention].
Kahán Z; Thurzó L
Orv Hetil; 2003 Mar; 144(13):597-603. PubMed ID: 12728784
[TBL] [Abstract][Full Text] [Related]
12. Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer.
Eng-Wong J; Hursting SD; Venzon D; Perkins SN; Zujewski JA
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1468-73. PubMed ID: 14693739
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer.
Johansson H; Baglietto L; Guerrieri-Gonzaga A; Bonanni B; Mariette F; Macis D; Serrano D; Sandri MT; Decensi A
Breast Cancer Res Treat; 2004 Nov; 88(1):63-73. PubMed ID: 15538047
[TBL] [Abstract][Full Text] [Related]
14. Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial.
Torrisi R; Mezzetti M; Johansson H; Barreca A; Pigatto F; Robertson C; Decensi A
Int J Cancer; 2000 Aug; 87(4):601-5. PubMed ID: 10918204
[TBL] [Abstract][Full Text] [Related]
15. N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells.
Herbert BS; Sanders BG; Kline K
Nutr Cancer; 1999; 34(2):121-32. PubMed ID: 10578478
[TBL] [Abstract][Full Text] [Related]
16. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of breast cancer with retinoids.
Veronesi U; De Palo G; Costa A; Formelli F; Marubini E; Del Vecchio M
J Natl Cancer Inst Monogr; 1992; (12):93-7. PubMed ID: 1535505
[TBL] [Abstract][Full Text] [Related]
18. Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients.
Torrisi R; Parodi S; Fontana V; Pensa F; Casella C; Barreca A; De Palo G; Costa A; Decensi A
Int J Cancer; 1998 Jun; 76(6):787-90. PubMed ID: 9626341
[TBL] [Abstract][Full Text] [Related]
19. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients.
Torrisi R; Parodi S; Fontana V; Rondanina G; Formelli F; Costa A; Boccardo F; Decensi A
Cancer Epidemiol Biomarkers Prev; 1994 Sep; 3(6):507-10. PubMed ID: 8000302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
